Affinity Biotech
This article was originally published in The Tan Sheet
Executive Summary
Patent & Trademark Office allows patents covering "neomorphic ibuprofen compositions and methods for their preparation" that "may result in less gastrointestinal irritation than currently marketed forms and cause no burning taste sensation to the user," the Aston, Penn.-based firm said Dec. 17. The new form can be taken as a liquid suspension, a chewable tablet, and as a nonchewable tablet/caplet form.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning